Dataset.

Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines [Dataset]

Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/360097
Digital.CSIC. Repositorio Institucional del CSIC
  • Aydillo, Teresa
  • Balsera-Manzanero, María
  • Rojo-Fernández, Amaya
  • Escalera, Alba
  • Salamanca-Rivera, Celia
  • Pachón, Jerónimo
  • Muñoz-García, M. M.
  • Sánchez-Cordero, María José
  • Sánchez-Céspedes, Javier
  • García-Sastre, Adolfo
  • Cordero, Elisa
Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is unknown. We aimed to understand the impact of mRNA COVID-19 vaccines administered concomitantly on the immune response to influenza vaccines. For this, 128 volunteers were vaccinated during the 22-23 influenza season. Three groups of vaccination were assembled: FLU vaccine only (46, 35%) versus volunteers that received the mRNA bivalent COVID-19 vaccines concomitantly to seasonal influenza vaccines, FluCOVID vaccine in the same arm (42, 33%) or different arm (40, 31%), respectively. Sera and whole blood were obtained the day of vaccination, +7, and +28 days after for antibody and T cells response quantification. As expected, side effects were increased in individuals who received the FluCOVID vaccine as compared to FLU vaccine only based on the known reactogenicity of mRNA vaccines. In general, antibody levels were high at 4 weeks post-vaccination and differences were found only for the H3N2 virus when administered in different arms compared to the other groups at day 28 post-vaccination. Additionally, our data showed that subjects that received the FluCOVID vaccine in different arm tended to have better antibody induction than those receiving FLU vaccines for H3N2 virus in the absence of pre-existing immunity. Furthermore, no notable differences in the influenza-specific cellular immune response were found for any of the vaccination groups. Our data supports the concomitant administration of seasonal influenza and mRNA COVID-19 vaccines., This work was supported by American Lung Association: [COVID-1034091]. Centro de Investigación Biomedica en Red de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea – NextGeneration EU (Grant Number CB21/13/00006); Consejeria de Economia, Conocimiento, Empresas y Universidad, Secretaria General de Universidades, Investigacion y Tecnologia, Junta de Andalucia, Spain (P18-RT-3320). SEM-CIVIC National Institute of Allergy and Infectious Diseases: [Grant Number 75N93019C00051]. CEIRR-CRIPT: [75N93021C00014]., Peer reviewed
 
DOI: http://hdl.handle.net/10261/360097
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/360097

HANDLE: http://hdl.handle.net/10261/360097
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/360097
 
Ver en: http://hdl.handle.net/10261/360097
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/360097

idUS. Depósito de Investigación de la Universidad de Sevilla
oai:idus.us.es:11441/158662
Artículo científico (article). 2023

CONCOMITANT ADMINISTRATION OF SEASONAL INFLUENZA AND COVID-19 MRNA VACCINES

idUS. Depósito de Investigación de la Universidad de Sevilla
  • Aydillo, Teresa
  • Balsera-Manzanero, Maria
  • Rojo-Fernandez, Amaya
  • Escalera, Alba
  • Salamanca Rivera, Celia
  • Pachón Díaz, Jerónimo
  • Muñoz-García, María Del Mar
  • Sánchez-Cordero, María José
  • Sanchez Cespedes, Javier
  • García-Sastre, Adolfo
  • Cordero Matia, María Elisa
Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is unknown. We aimed to understand the impact of mRNA COVID-19 vaccines administered concomitantly on the immune response to influenza vaccines. For this, 128 volunteers were vaccinated during the 22-23 influenza season. Three groups of vaccination were assembled: FLU vaccine only (46, 35%) versus volunteers that received the mRNA bivalent COVID-19 vaccines concomitantly to seasonal influenza vaccines, FluCOVID vaccine in the same arm (42, 33%) or different arm (40, 31%), respectively. Sera and whole blood were obtained the day of vaccination, +7, and +28 days after for antibody and T cells response quantification. As expected, side effects were increased in individuals who received the FluCOVID vaccine as compared to FLU vaccine only based on the known reactogenicity of mRNA vaccines. In general, antibody levels were high at 4 weeks post-vaccination and differences were found only for the H3N2 virus when administered in different arms compared to the other groups at day 28 post-vaccination. Additionally, our data showed that subjects that received the FluCOVID vaccine in different arm tended to have better antibody induction than those receiving FLU vaccines for H3N2 virus in the absence of pre-existing immunity. Furthermore, no notable differences in the influenza-specific cellular immune response were found for any of the vaccination groups. Our data supports the concomitant administration of seasonal influenza and mRNA COVID-19 vaccines., Premio Mensual Publicación Científica Destacada de la US. Facultad de Medicina




Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/360096
Artículo científico (article). 2024

CONCOMITANT ADMINISTRATION OF SEASONAL INFLUENZA AND COVID-19 MRNA VACCINES

Digital.CSIC. Repositorio Institucional del CSIC
  • Aydillo, Teresa
  • Balsera-Manzanero, María
  • Rojo-Fernández, Amaya
  • Escalera, Alba
  • Salamanca-Rivera, Celia
  • Pachón, Jerónimo
  • Muñoz-García, M. M.
  • Sánchez-Cordero, María José
  • Sánchez-Céspedes, Javier
  • García-Sastre, Adolfo
  • Cordero, Elisa
Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is unknown. We aimed to understand the impact of mRNA COVID-19 vaccines administered concomitantly on the immune response to influenza vaccines. For this, 128 volunteers were vaccinated during the 22-23 influenza season. Three groups of vaccination were assembled: FLU vaccine only (46, 35%) versus volunteers that received the mRNA bivalent COVID-19 vaccines concomitantly to seasonal influenza vaccines, FluCOVID vaccine in the same arm (42, 33%) or different arm (40, 31%), respectively. Sera and whole blood were obtained the day of vaccination, +7, and +28 days after for antibody and T cells response quantification. As expected, side effects were increased in individuals who received the FluCOVID vaccine as compared to FLU vaccine only based on the known reactogenicity of mRNA vaccines. In general, antibody levels were high at 4 weeks post-vaccination and differences were found only for the H3N2 virus when administered in different arms compared to the other groups at day 28 post-vaccination. Additionally, our data showed that subjects that received the FluCOVID vaccine in different arm tended to have better antibody induction than those receiving FLU vaccines for H3N2 virus in the absence of pre-existing immunity. Furthermore, no notable differences in the influenza-specific cellular immune response were found for any of the vaccination groups. Our data supports the concomitant administration of seasonal influenza and mRNA COVID-19 vaccines., This work was partly supported by Consejería de Transformación Económica, Industria, Conocimiento y Universidades and FEDER. It is also partly supported by CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIAID funded Center of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014) to A.G.-S and T.A.; and by SEM-CIVIC, a NIAID funded Collaborative Influenza Vaccine Innovation Center (contract #75N93019C00051) to A.G.-S. T. A was also funded by the American Lung Association. JSC and EC also were supported by CIBERINFEC – Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU (CB21/13/00006)., Peer reviewed




Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/360097
Dataset. 2024

CONCOMITANT ADMINISTRATION OF SEASONAL INFLUENZA AND COVID-19 MRNA VACCINES [DATASET]

Digital.CSIC. Repositorio Institucional del CSIC
  • Aydillo, Teresa
  • Balsera-Manzanero, María
  • Rojo-Fernández, Amaya
  • Escalera, Alba
  • Salamanca-Rivera, Celia
  • Pachón, Jerónimo
  • Muñoz-García, M. M.
  • Sánchez-Cordero, María José
  • Sánchez-Céspedes, Javier
  • García-Sastre, Adolfo
  • Cordero, Elisa
Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is unknown. We aimed to understand the impact of mRNA COVID-19 vaccines administered concomitantly on the immune response to influenza vaccines. For this, 128 volunteers were vaccinated during the 22-23 influenza season. Three groups of vaccination were assembled: FLU vaccine only (46, 35%) versus volunteers that received the mRNA bivalent COVID-19 vaccines concomitantly to seasonal influenza vaccines, FluCOVID vaccine in the same arm (42, 33%) or different arm (40, 31%), respectively. Sera and whole blood were obtained the day of vaccination, +7, and +28 days after for antibody and T cells response quantification. As expected, side effects were increased in individuals who received the FluCOVID vaccine as compared to FLU vaccine only based on the known reactogenicity of mRNA vaccines. In general, antibody levels were high at 4 weeks post-vaccination and differences were found only for the H3N2 virus when administered in different arms compared to the other groups at day 28 post-vaccination. Additionally, our data showed that subjects that received the FluCOVID vaccine in different arm tended to have better antibody induction than those receiving FLU vaccines for H3N2 virus in the absence of pre-existing immunity. Furthermore, no notable differences in the influenza-specific cellular immune response were found for any of the vaccination groups. Our data supports the concomitant administration of seasonal influenza and mRNA COVID-19 vaccines., This work was supported by American Lung Association: [COVID-1034091]. Centro de Investigación Biomedica en Red de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea – NextGeneration EU (Grant Number CB21/13/00006); Consejeria de Economia, Conocimiento, Empresas y Universidad, Secretaria General de Universidades, Investigacion y Tecnologia, Junta de Andalucia, Spain (P18-RT-3320). SEM-CIVIC National Institute of Allergy and Infectious Diseases: [Grant Number 75N93019C00051]. CEIRR-CRIPT: [75N93021C00014]., Peer reviewed




1106